1551P_PR - Patterns of patients stopping their anti-cancer drug due to its associated side effects in France, Germany, Italy, Spain and UK (EU5)

Date 28 September 2014
Event ESMO 2014
Session Poster Display session
Topics Complications of Treatment
Supportive Care
Presenter Reena Khanna
Citation Annals of Oncology (2014) 25 (5): 1-41. 10.1093/annonc/mdu438
Authors R. Khanna1, C. Anger2
  • 1Client Service Oncology, IMS Health, N1 9JY - London/GB
  • 2Oncology, IMS HEALTH, LONDON/GB



Number of patients stopping their anticancer drug due to its side effects varies across several cancers and countries in EU5; this may influence patient outcomes. This study describes cessation of anticancer drugs due to its side effects in clinical practice across EU5.


IMS Oncology Analyzer™ (OA) was used for this study, a patient database collected quarterly through a physician panel survey. OA reports on patient history information related to their treatment across all cancers. Most recent data (Jan-Dec 2013) was used. As patients can experience multiple side effects these numbers may be over 100%. Patients selected for this study have discontinued their therapy due to side effects exclusively.


From a sample of 7899 patients, 531 were identified as having their anti-cancer drug treatment stopped due to its side effects. Among them, 461 (87%) were on a cytotoxic drug and 70 (13%) on a hormonal. Overall, patients were mainly diagnosed with Breast (22%), Colorectal (CRC) (14%), and Non Small Cell Lung Cancer (NSCLC) (13%). Main side effects for those patients were neutropenia (36%), nausea/vomiting (23%), anaemia (21%), neuropathy (17%) and mucositis (15%). Among patients that stopped taking their anti-cancer drug due to side effects: · Breast cancer: 57% received cytotoxics and 43% hormonals. Common side effects for stopping cytotoxic drugs were neutropenia at 43% and pain for hormonals at 59%. Drugs causing cessation included anastrazole (16%), letrozole (11%) and tamoxifen (11%). · CRC: patients received capecitabine/oxaliplatin (29%), 5FU/oxaliplatin (16%) and capecitabine (14%). Main side effects included neutropenia (53%), diarrhea (39%), neuropathy (39%) and nausea/vomiting (24%). · NSCLC: patients received cisplatin/pemetrexed (29%), and cisplatin/vinorelbine (19%). The main reason for cessation was nausea/vomiting (37%), neutropenia (29%) and anaemia (22%).


7% of cancer patients across EU5 countries stopped taking their anti-cancer drug due to its side effects. Despite the availability of supportive care treatments, there is still a need to improve management of side effects to enable better patient outcomes.


All authors have declared no conflicts of interest.